¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (SoLA 2024) 2ÀÏÂ÷ : 2024-04-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (SoLA 2024) 2ÀÏÂ÷ : 2024-04-06
±³À°ÀÏÀÚ : 2024-04-06
±³À°Àå¼Ò : ½Ã±×´Ï¿¤ ºÎ»ê 4Ãþ room1,2,3

±³À°ÁÖÁ¦ : 2024 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (SoLA 2024) 2ÀÏÂ÷

ÁÖÃÖ±â°ü : Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ
´ã´çÀÚ : SoLA2024 Áغñ»ç¹«±¹
¿¬¶ôó : 02-6734-1011  

À̸ÞÀÏ : sola2024@planbear.co.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ

¼¼ºÎ¼ö°­·á : 70,000¿ø  

ºñ°í ±³¼ö/ºÀÁ÷ÀÇ/°³¿øÀÇ : »çÀü µî·Ï (ȸ¿ø) 40,000¿ø,(ºñȸ¿ø)60,000¿ø. ÇöÀå µî·Ï (ȸ¿ø)50,000¿ø, (ºñȸ¿ø)70,000 ÀüÀÓÀÇ/¿µ¾ç»ç/¿îµ¿»ç/°£È£»ç/¿¬±¸¿ø/±âŸ Âü°¡ÀÚ: »çÀüµî·Ï (ȸ¿ø)20.000¿ø,(ºñȸ¿ø)40,000¿ø ÇöÀåµî·Ï(ȸ¿ø)30,000¿ø, (ºñȸ¿ø) 50,000¿ø Çлý/Àü°øÀÇ/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/65¼¼ ÀÌ»ó: ¹«·á


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 07:30~07:50 The lastes clinical trial of Atorvastatin, LODESTAR study Á¤Ã¢Èñ(¿ï»êÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04¿ù 06ÀÏ Room1 07:50~08:00 Panel Discussion ()

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 08:30~08:50 Bempedoic acid ±èÇзÉ(¼­¿ïÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 08:50~09:10 Semaglutide À±Á¾Âù(°¡Å縯ÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 09:10~09:30 Inclisiran ÀüÀçÇÑ(°æºÏÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04¿ù 06ÀÏ Room1 09:30~10:00 Panel Discussion ()

ÈÞ½Ä 04¿ù 06ÀÏ 10:00~10:15 Break ()

±âŸ 04¿ù 06ÀÏ 10:15~10:20 Opening Address ()

±³À°½Ã°£ 04¿ù 06ÀÏ Room1,2,3 10:20~11:00 Heart-Immune-Brain network in the pathogenesis of cardio-cerebrovascular disease ¿À±¸ÅÃ(ÀÌÈ­¿©´ë »ý¸í°úÇаú)

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 12:20~12:40 Cutting edge care of pitavastatin with ezetimibe combination therapy ¹Ú°æÀÏ(µ¿¾ÆÀÇ´ë ¼øȯ±â³»°ú)

Åä·Ð 04¿ù 06ÀÏ Room1 12:40~12:50 Panel Discussion ()

ÈÞ½Ä 04¿ù 06ÀÏ 12:50~13:20 Break ()

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 13:30~13:50 KSoLA- Deciphering lipid enigmas: exploring TRL, triglycerides and remnant cholesterol as residual lipid risks and treatment targets ±èº´Áø(¼º±Õ°üÀÇ´ë ¼øȯ±â³»°ú)

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 13:50~14:10 KDA-  Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk ÀÌÁØ¿±(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 14:10~14:30 KSSO- CVOTs using non-GLP-1 based anti-obesity medications and bariatric surgery È«ÁØÈ­(À»ÁöÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04¿ù 06ÀÏ Room1 14:30~15:00 Panel Discussion ()

ÈÞ½Ä 04¿ù 06ÀÏ 15:00~15:20 Break ()

±³À°½Ã°£ 04¿ù 06ÀÏ Room1,2,3 15:20~16:00 Two key biologic systems for cardiometabolic syndrome based on CAP1 : Resistin & PCSK9 ±èÈ¿¼ö(¼­¿ïÀÇ´ë ¼øȯ±â³»°ú)

ÈÞ½Ä 04¿ù 06ÀÏ 16:00~16:10 Break ()

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 16:10~16:30 Dyslipidemia in Elderly-general concept ±è±¤ÁØ(¿¬¼¼ÀÇ´ë ³ë³â³»°ú)

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 16:30~16:50 Dyslipidemia in CKD À¯ÅÂÇö(¿¬¼¼ÀÇ´ë ½ÅÀå³»°ú)

±³À°½Ã°£ 04¿ù 06ÀÏ Room1 16:50~17:10 Dyslipidemia in adolescents and young adults ÀÌÀº¿µ(°¡Å縯ÀÇ´ë ³»ºÐºñ³»°ú)

Åä·Ð 04¿ù 06ÀÏ Room1 17:10~17:40 Panel Discussion ()

±âŸ 04¿ù 06ÀÏ Room1,2,3 17:40~18:00 Closing Ceremony ()

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ (SoLA 2024) 2ÀÏÂ÷ : 2024-04-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2024³â Á¦1Â÷ ÇÁ·ÎÆ÷Æú ÁøÁ¤±³À° : 2024-04-07
´ÙÀ½±Û Á¦66Â÷ ´ëÇÑÀÌ°úÇÐȸ Çмú´ëȸ : 2024-04-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
375 ¼­¿ï 2018³â Á¦31ȸ ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ Á¤±âÇмú´ëȸ ¹× ÃÑȸ : 2018-08-25 0 627 2018-08-15
374 ÀÎõ ´ëÇѽ½°üÀýÇÐȸ Á¦5ȸ Korea-Japan Knee Osteotomy Symposium : 2018-08-25 0 1,336 2018-08-15
373 °­¿ø 2018³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ ¿¬±¸È¸¿¬ÇÕ Á¤±âÇмú´ëȸ : 2018-08-24 0 342 2018-08-15
372 ¼­¿ï ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Ư°­ : 2018-08-23 0 302 2018-08-15
371 Àü³² ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ È£³²Áöȸ 283Â÷ ¿ù·ÊÁý´ãȸ : 2018-08-23 0 631 2018-08-15
370 ¼­¿ï ´ëÇÑ°³¿øÀÇÇùÀÇȸ Á¦4ȸ µÎ°æºÎ ÃÊÀ½ÆÄ ¿¬¼ö ¼¼¹Ì³ª : 2018-09-30 0 1,946 2018-08-08
369 ´ë±¸ ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ ´ë±¸¡¤°æºÏ ÁöºÎȸ Á¦2Â÷ ÇмúÁý´ãȸ : 2018-09-20 0 530 2018-08-08
368 °æ³² ´ëÇѼҾưúÇÐȸ °³Á¤µÈ °¡¿Í»çÅ°º´ Áø·áÁöħ¿Ü 1°Ç : 2018-09-20 0 775 2018-08-08
367 °­¿ø ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ °­¿øÁöȸ Áý´ãȸ : 2018-09-15 0 1,158 2018-08-08
366 °æ±â ±¹¸³¾Ï¼¾ÅÍ ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ǹ®´õ½Ê°úÁ¤ : 2018-09-15 0 561 2018-08-08
365 Àü³² Çѱ¹°£´ãÃé¿Ü°úÇÐȸ Á¦13Â÷ ±¹Á¦½Ì±ÛÅäÇȽÉÆ÷Áö¿ò : 2018-09-14 0 1,026 2018-08-08
364 ºÎ»ê ºÎ»ê¼Ò¾Æ°úÇÐȸ Á¤±â Çмú Áý´äȸ : 2018-09-13 0 1,470 2018-08-08
363 ´ë±¸ ´ëÇÑÄ¡¸ÅÇÐȸ ´ë±¸°æºÏÁöȸ 2018 Ãß°è ½ÉÆ÷Áö¿ò : 2018-09-13 0 448 2018-08-08
362 ÀüºÏ Á¦6ȸ ÀüºÏ´ëÇб³º´¿ø Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ ½ÉÆ÷Áö¾ö : 2018-09-11 0 353 2018-08-08
361 ¼­¿ï ´ëÇѼҾư¨¿°ÇÐȸ Á¦17ȸ ¿¬¼ö°­Á : 2018-09-09 0 432 2018-08-08
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷